Inclusion Criteria:

1. Patients must histologically or cytologically be diagnosed to have an advanced solid
cancer. (phaseI)

2. Advanced/metastatic/recurred gastric cancer(PhaseII)

3. ECOG performance status ≤ 2

4. Patients have proper bone marrow, kidney, liver function and patients do not have
remarkable dysfunction of heart and lung: WBC≥4000/mm3; Platelet ≥100,000/mm3;
Hemoglobin≥9.0g/dL; ANC≥ 1,500 /mm3; Creatinine ≤ 1.5mg/dL; AST/ALT/ALP ≤ 3 X the
upper limit of normal; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X the upper limit
of normal but <5 if liver or bone metastasis is present

Exclusion Criteria:

1. Patients with blood tumor (ex, leukemia), uncontrolled infectious disease, neurologic
disorders, metastasis to CNS or ileus (patients requiring non-oral administration of
anti-biotics to treat active bacterial infection are nor eligible, but patients can
participate in the trial after complete eradication or control of the infection)

2. Patients who have received bone marrow transplant or are to receive bone marrow
transplant.

3. Patients who had the medical history of atrial or ventricular arrhythmia or
congestive heart failure or received medical treatment for myocardial infarction
within 6 months.